Forte Biosciences (FBRX) Net Cash Flow (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Net Cash Flow of -$18.7 million for Q1 2026, down 179.31% year-over-year from $23.6 million in Q1 2025, and down 13.66% quarter-over-quarter from -$16.5 million in Q4 2025.
Forte Biosciences (FBRX) Net Cash Flow (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Net Cash Flow for 11 consecutive years, with -$18.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 179.31% year-over-year to -$18.7 million; the TTM figure through Mar 2026 stood at $12.4 million (down 19.82% YoY), while the FY2025 annual figure was $54.7 million, up 467.55% from the prior year.
- Net Cash Flow fell to -$18.7 million in Q1 2026 per FBRX's latest filing, from -$16.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $60.3 million in Q2 2025 and bottomed at -$18.7 million in Q1 2026.
- Historically, Net Cash Flow has averaged $1.5 million across 5 years, with a median of -$5.2 million in 2023.
- On a YoY basis, Net Cash Flow climbed as much as 1113.93% in 2025 and fell as far as 380.14% in 2025.
- Forte Biosciences' Net Cash Flow stood at -$2.9 million in 2022, then slumped by 207.33% to -$9.1 million in 2023, then jumped by 164.91% to $5.9 million in 2024, then plunged by 380.14% to -$16.5 million in 2025, then dropped by 13.66% to -$18.7 million in 2026.
- Business Quant data shows FBRX's Net Cash Flow at -$18.7 million in Q1 2026, -$16.5 million in Q4 2025, and -$12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | -8.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.59 Mn |
| Jun 30, 2026 | -8.59 Mn |
| Mar 31, 2026 | -18.73 Mn |
| Mar 31, 2026 | -18.73 Mn |
| Dec 31, 2025 | -16.48 Mn |
| Dec 31, 2025 | -16.48 Mn |
| Sep 30, 2025 | -12.73 Mn |
| Sep 30, 2025 | -12.73 Mn |
| Jun 30, 2025 | 60.29 Mn |
| Jun 30, 2025 | 60.29 Mn |
| Mar 31, 2025 | 23.61 Mn |
| Mar 31, 2025 | 23.61 Mn |
| Dec 31, 2024 | 5.88 Mn |
| Dec 31, 2024 | 5.88 Mn |
| Sep 30, 2024 | -8.14 Mn |
| Sep 30, 2024 | -8.14 Mn |
| Jun 30, 2024 | -5.95 Mn |
| Jun 30, 2024 | -5.95 Mn |
| Mar 31, 2024 | -6.68 Mn |
| Mar 31, 2024 | -6.68 Mn |